BioVaxys Extends Private Placement Closing Date
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB), a pioneering clinical-stage biopharmaceutical company, is excited to announce an extension regarding its previously announced non-brokered private placement offering of company units. Each unit is priced at $0.05 and consists of one common share and one warrant.
Details of the Private Placement
To allow more investors to participate, the company is extending the closing date of its fourth and final tranche of the private placement, originally scheduled for February 7, 2025. This new date is set no later than February 14, 2025. The funds raised in this tranche will be utilized for working capital purposes.
Understanding the Units and Warrants
Each unit in the offering comprises one common share and one warrant, with each warrant granting the holder the right to purchase an additional share at an exercise price of $0.15 for a duration of 24 months post-issuance. This structure is designed to incentivize investor participation and support the growth of the company.
Company Overview
BioVaxys Technology Corp. is dedicated to enhancing patient lives through innovative immunotherapies. Utilizing its proprietary DPX™ immune-educating technology platform and the HapTenix© 'neoantigen' tumor cell construct platform, BioVaxys focuses on treating various conditions such as cancer, infectious diseases, and immunological disorders.
Innovations in Immunotherapy
The DPX™ platform is a patented antigen delivery system that combines multiple bioactive molecules, promoting targeted and durable immune responses. It has shown promising results in both pre-clinical and clinical studies, indicating strong potential for impacting cancer and infectious disease treatment.
Public Trading and Market Position
BioVaxys is publicly traded under the stock symbol "BIOV" on the Canadian Securities Exchange, with additional listings on the Frankfurt Bourse and the OTC Markets in the US. This public presence enhances its ability to raise funds for ongoing research and development.
Management and Contact Information
James Passin, the Chief Executive Officer, leads the company with a vision of transforming cancer treatment through cutting-edge biotechnology. Interested parties can contact him at +1 740 358 0555 for inquiries related to the private placement or the company's advancements in immunotherapies.
Frequently Asked Questions
What is the purpose of the private placement?
The private placement is designed to secure additional funding to support BioVaxys Technology Corp.'s working capital requirements.
How long is the warrant valid for?
Each warrant is valid for a period of 24 months following its issuance, allowing investors additional time to make use of their stock options.
Where can I learn more about BioVaxys?
More information about BioVaxys can be found on their official website, which provides resources about their technology and ongoing projects.
What technologies does BioVaxys utilize?
BioVaxys employs the DPX™ platform and the HapTenix© technology to develop innovative solutions for cancer and infectious diseases.
Who leads BioVaxys Technology Corp.?
The company is led by James Passin, who serves as Chief Executive Officer and is committed to enhancing patient lives through novel immunotherapy approaches.
